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Comment: 
Mulick and colleagues report long-term follow-up data from two randomised controlled trials (RCTs) 
of depression treatment for people with comorbid depression and cancer1. The main trials, SMaRT 
Oncology-2 for people with good prognosis cancers, and SMaRT Oncology-3 for patients with poor 
prognosis cancers, aimed to determine whether “Depression Care for People with Cancer” (DCPC) 
reduced depression symptoms. In their analysis of the follow-up data, the researchers aimed to 
identify whether DCPC also improved survival rates. Across the two RCTs 642 patients were recruited 
and randomised to receive DCPC, or treatment as usual.  
Much of the association between depression and cancer can be explained by high smoking 
prevalence among people with depression2. We know that people with depression are about twice 
as likely to smoke, and are more heavily addicted compared with the general population3. These 
inequalities contribute to a reduction in life-expectancy of almost 14 years for people with 
depression compared to those without depression2, even though they are motivated to stop 
smoking3. Given this, we were surprised that: 1) participants’ smoking status was not reported, and 
2) the comorbid association between mental illness and smoking was not discussed. Smoking is the 
leading cause of cancer, and stopping smoking after diagnosis of cancer can improve prognostic 
outcomes4. Moreover, stopping smoking is also associated with improvements in mental health, 
even in people with psychiatric conditions5. There is therefore a strong case for offering parallel 
treatment of smoking and depression; by not offering smokers with depression help to quit we may 
be worsening both their mental and physical health.  
We are currently investigating the implementation of smoking cessation treatment alongside routine 
psychological care for smokers with depression and/or anxiety. The preliminary qualitative work that 
we have conducted suggests that psychological therapists have the proficiency to deliver such an 
intervention and feel that part of their role is to help willing clients to make healthy lifestyle 
changes. In addition, we have identified the potential for a similar intervention to be tested in other 
primary or secondary care settings for smokers with comorbid mental-illness and smoking-related 
conditions, such as cancer or COPD. Due to the enormous beneficial impact that stopping smoking 
has on health outcomes, smoking cessation interventions are some of the most cost-effective 
treatments available to health services. Our research provides preliminary evidence that there are 
missed-opportunities to deliver such treatments in NHS services, and potentially in similar health 
care settings worldwide.  
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